share_log

EFFECT: Others

EFFECT: Others

EFFECT:其他
美股SEC公告 ·  05/03 06:06
Moomoo AI 已提取核心訊息
Conduit Pharmaceuticals Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its submission effective as of May 2, 2024. The company's filing, identified by accession number 0001493152-24-017464 and submission type POS AM, has been acknowledged by the SEC, marking a pivotal step in Conduit Pharmaceuticals' regulatory journey. The effectiveness of this submission is a key development for the company, which is listed under the CIK number 0001896212 and file number 333-275056.
Conduit Pharmaceuticals Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its submission effective as of May 2, 2024. The company's filing, identified by accession number 0001493152-24-017464 and submission type POS AM, has been acknowledged by the SEC, marking a pivotal step in Conduit Pharmaceuticals' regulatory journey. The effectiveness of this submission is a key development for the company, which is listed under the CIK number 0001896212 and file number 333-275056.
Conduit Pharmicals Inc.取得了重要的里程碑,美國證券交易委員會(SEC)宣佈其提交的文件自2024年5月2日起生效。該公司的申請以註冊號0001493152-24-017464確定,提交類型爲POS AM,已得到美國證券交易委員會的認可,這標誌着Conduit Pharmaceuticals監管之旅邁出了關鍵的一步。本次提交的有效性是該公司的一項關鍵進展,該公司在CIK上市,編號爲0001896212,文件編號爲333-275056。
Conduit Pharmicals Inc.取得了重要的里程碑,美國證券交易委員會(SEC)宣佈其提交的文件自2024年5月2日起生效。該公司的申請以註冊號0001493152-24-017464確定,提交類型爲POS AM,已得到美國證券交易委員會的認可,這標誌着Conduit Pharmaceuticals監管之旅邁出了關鍵的一步。本次提交的有效性是該公司的一項關鍵進展,該公司在CIK上市,編號爲0001896212,文件編號爲333-275056。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息